This clinical commentary discusses the occurrence of drug-induced aseptic meningitis in patients undergoing natalizumab treatment and other immunotherapies.
FoleyRWTaggNTSchindlerMKet al. Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis. Mult Scler2017; 23: 1424–1427.
2.
MorisGGarcia-MoncoJC.The challenge of drug-induced aseptic meningitis revisited. JAMA Int Med2014; 174: 1511–1512.
3.
BharatVEckertKKangMet al. Incidence and natural history of intravenous immunoglobulin–induced aseptic meningitis: A retrospective review at a single tertiary care center. Transfusion2015; 55: 2597–2605.
4.
MishraRSinghVPritchardCH.Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis. Rheumatol Int2011; 31: 481–484.
5.
RothhammerVMuschaweckhAGasteigerGet al. α4-integrins control viral meningoencephalitis through differential recruitment of T helper cell subsets. Acta Neuropathol Commun2014; 2: 272.
6.
CherinPMarieIMichalletMet al. Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence. Autoimmunity Rev2016; 15: 71–81.
